Coverage of the ASCO20 Virtual Scientific Program
Posted by Elsbeth Headley
Working together with our sister website Medicine Matters oncology, Springer Healthcare IME has been busy updating our renal cell carcinoma (RCC) hub with all of the hot topics and breaking news from the recent ASCO20 Virtual Scientific Program held on May 29–31.
Despite the meeting converting to a virtual format owing to the COVID-19 pandemic, we were still able to bring the latest news and views of leading experts direct to our audience of oncology healthcare professionals across the globe.
Highlights include:
- News: For patients with treatment-naïve advanced renal cell carcinoma, pembrolizumab plus axitinib offers superior overall survival (OS) to sunitinib, confirms an updated analysis from the KEYNOTE-426 trial.
- Interview: Toni Choueiri reports preliminary results from the FRACTION-RCC study showing encouraging efficacy of nivolumab plus ipilimumab in advanced renal cell carcinoma patients who have progressed on prior immunotherapy.
- Interview: Chung-Han Lee reports on the final analysis of KEYNOTE-146/Study 111 trial of lenvatinib plus pembrolizumab in metastatic clear-cell RCC after immune checkpoint inhibitor therapy.
All of our this and more independent content and archived material on RCC can be accessed here.
Educational grant disclosure: This program is made possible thanks to an independent educational grant from Pfizer and Merck KGaA